Randomized to receive either ELIQUIS 2.5 mg or 5 mg, or placebo twice Treatment), a randomized, double-blind, multicenter trial, includedĢ,486 patients with prior VTE who had completed 6 to 12 months ofĪnticoagulation treatment for DVT or PE and for whom there was clinicalĮquipoise about the need for continued anticoagulation. Mortality without an increase in major bleeding versus placebo.”ĪMPLIFY-EXT ( Apixaban after the initial Management of Pu LmonaryĮmbol Ism and deep vein thrombosis with First-line therap Y- EXTended Reduced the composite risk of recurrent venous thromboembolism and total “In theĪMPLIFY-EXT trial, which added an additional year of treatment, ELIQUIS Hospital, Perugia, Italy and lead investigator of the study. Internal and Cardiovascular Medicine and Stroke-Unit, University Medicine, University of Perugia, Italy director of the Department of Six-to-twelve-month treatment period, suggesting the need for additional Thromboembolism event after completing the currently recommended “Up to 10 percent of patients will experience a recurrent venous Meeting of the American Society of Hematology (ASH). Medicine and announced at a press briefing during the 54th Annual Theįindings were published online today in The New England Journal of The 2.5 mg treatment group (3.2%) was similar to the placebo group. (4.3%) was higher versus the placebo group (2.7%), while the rate for The rate of the composite of major bleedingĪnd clinically relevant non-major bleeding for the 5 mg treatment group The rate of the primary safety outcome of major bleeding was comparableĪcross treatment groups (0.2 % for ELIQUIS 2.5 mg 0.1 % for ELIQUIS 5 Outcomes, were statistically significant (p<0.001). Both of these endpoints, the primary and secondary efficacy Placebo group, compared with 1.7% in both the ELIQUIS 2.5 mg and 5 mg Trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily,ĭemonstrated superiority versus placebo in the reduction of theĬomposite endpoint of symptomatic, recurrent VTE and death from anyĬause (11.6% in the placebo group, compared with 3.8% and 4.2% in theĮLIQUIS 2.5 mg and 5 mg groups, respectively, P<0.001), the primaryĮLIQUIS also was superior to placebo for the predefined secondaryĮfficacy outcome of recurrent VTE and VTE-related death (8.8% in the Including deep vein thrombosis (DVT) or pulmonary embolism (PE). Of recurrent venous thromboembolism (VTE) in 2,486 patients who hadĪlready completed 6 to 12 months of anticoagulation treatment for VTE, (apixaban) over a one-year period compared to placebo for the prevention (NYSE: PFE) today announced the results of the Phase 3ĪMPLIFY-EXT trial, which evaluated treatment with ELIQUIS ® New Phase 3 Results Published today in New England Journal of Medicine and Will Be Presented as a Late-Breaker at American Society for Hematology Annual Meeting
0 kommentar(er)
